The Trump administration proposed a rule on Thursday that would severely limit future U.S. investment in the Chinese biotechnology sector. The Treasury Department drafted the proposal to implement the Comprehensive Outbound Investment National Security Act, which targets industries deemed a threat to national security. By adding biotechnology to the list of restricted sectors, the department placed it alongside semiconductors, artificial intelligence, and quantum technology. According to the research firm Veda, the proposal would prohibit U.S. companies from entering financial transactions with Chinese biotech firms or manufacturers of related equipment and tools. The rule would still allow American drugmakers to purchase rights to medicines invented in China.